Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | terminated | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689656 | A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2026 |
| clinicaltrials |
| NCT07690878 | PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer | not yet recruiting | Phase 2 | 35 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02520154 | Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04175431 | Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | recruiting | Phase 2 | 100 | University of WashingtonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05127824 | Autologous Dendritic Cell Vaccine in Kidney Cancer | recruiting | Phase 2 | 42 | Jodi MaranchieOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06029998 | Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion(BORXPTEN) | active not recruiting | Phase 2 | 22 | University of UtahOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06526299 | Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease | recruiting | Phase 2 | 51 | University of WashingtonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT00087685 | RAD001 in Recurrent Endometrial Cancer Patients | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03391479 | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04718584 | the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | completed | Phase 2 | 27 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07209865 | 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | completed | Phase 2 | 82 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07552168 | INSPIRE: INnovative SABR for Prostate Cancer All IREland | recruiting | Phase 2 | 136 | Cancer Trials IrelandNETWORK | 2 | Jul 6, 2026 | clinicaltrials |
| NCT00403169 | Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer | completed | Phase 2 | 28 | The Cleveland ClinicOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02964078 | Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05256472 | A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 2 | 28 | AkesoINDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07087158 | A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00183820 | Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | completed | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06401980 | Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | recruiting | Phase 2 | 162 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05171387 | Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | completed | Phase 2 | 78 | BayerINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07125391 | Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer | recruiting | Phase 2 | 136 | Bai-Rong XiaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07313241 | Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)((RANGER)) | recruiting | Phase 2 | 68 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | recruiting | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06568562 | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer(PRO-XL) | recruiting | Phase 2 | 32 | University of UtahOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | not yet recruiting | Phase 2 | 28 | GOG FoundationNETWORK | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672860 | Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors(PURIFY) | recruiting | Phase 2 | 146 | Jinling Hospital, ChinaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer(Phase II) | not yet recruiting | Phase 2 | 49 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03832361 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | recruiting | Phase 2 | 50 | Alessandro SantinOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04619069 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06457919 | A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07652073 | A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07667751 | An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer | recruiting | Phase 2 | 35 | Bai-Rong XiaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 8, 2026source: clinicaltrials